Unique ID issued by UMIN | UMIN000014058 |
---|---|
Receipt number | R000016369 |
Scientific Title | Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes |
Date of disclosure of the study information | 2014/05/26 |
Last modified on | 2018/04/03 21:42:23 |
Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes
Visceral fat reduction by SGLT2 inhibitor Ipragliflozin
Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes
Visceral fat reduction by SGLT2 inhibitor Ipragliflozin
Japan |
type 2 diabetes mellitus
Medicine in general | Endocrinology and Metabolism |
Malignancy
NO
To examine the change in fat and lean volume by treating with SGLT2 inhibitor Ipragliflozin in patients with type 2 diabetes
Efficacy
Exploratory
Explanatory
Phase IV
Change in visceral fat volume
1) glucose and lipid metabolism, 2) Abdominal circumference, 3) Weight, 4) Insulin secretion and insulin resistance, 5) microalbuminuria, 6) blood test(complete blood count, electrolytes, kidney and liver function test), 7) several biomarkers (adipokines, oxidative stress, etc)
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) outpatients with type 2 diabetes who will start taking Ipragliflozin, 2) well-controlled in terms of blood pressure and lipids, 3) made a written informed consent
1) hypersensitivity to Ipragliflozin, 2) unstable diabetic retinopathy, 3) severe hepatic, renal, or heart dysfunction, 4) pregnancy, 5) patients who are inadequate to enter this study due to the other reasons by physician's judgments
26
1st name | |
Middle name | |
Last name | Hideaki Miyoshi |
Hokkaido University Hospital
Department of Internal Medicine II
Nishi 5, Kita 14, Kita-ku, Sapporo, Hokkaido, Japan
011-706-5915
hmiyoshi@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Hideaki Miyoshi |
Hokkaido University Hospital
Department of Internal Medicine II
Nishi 5, Kita 14, Kita-ku, Sapporo, Hokkaido, Japan
011-706-5915
hmiyoshi@med.hokudai.ac.jp
Hokkaido University Hospital
Astellas Pharma Inc.
Other
Japan
NO
2014 | Year | 05 | Month | 26 | Day |
Published
Main results already published
2014 | Year | 05 | Month | 23 | Day |
2014 | Year | 05 | Month | 27 | Day |
2015 | Year | 03 | Month | 01 | Day |
To examine the change in fat and lean volume by treating with SGLT2 inhibitor Ipragliflozin in patients with type 2 diabetes
2014 | Year | 05 | Month | 24 | Day |
2018 | Year | 04 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016369
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |